Dasapharm Limited Filleted Accounts Cover |
Company No. 09325869 | |||||||||
Dasapharm Limited Directors Report Registrar |
The Directors present their report and the accounts for the year ended 31 December 2024. | |||||||||
Principal activities | |||||||||
Directors | |||||||||
The Directors who served at any time during the year were as follows: | |||||||||
A. Katzman | |||||||||
D. Mevzos | |||||||||
Signed on behalf of the board | |||||||||
D. Mevzos | |||||||||
Director | |||||||||
09 July 2025 | |||||||||
Dasapharm Limited Balance Sheet Registrar |
at | ||||||||||
Company No. | Notes | 2024 | 2023 | |||||||
$ | $ | |||||||||
Fixed assets | ||||||||||
Intangible assets | 4 | |||||||||
Tangible assets | 5 | |||||||||
Current assets | ||||||||||
Stocks | 6 | |||||||||
Debtors | 7 | |||||||||
Cash at bank and in hand | ||||||||||
Creditors: Amount falling due within one year | 8 | ( | ( | |||||||
Net current liabilities | ( | ( | ||||||||
Total assets less current liabilities | ( | ( | ||||||||
Net liabilities | ( | ( | ||||||||
Capital and reserves | ||||||||||
Called up share capital | ||||||||||
Profit and loss account | 10 | ( | ( | |||||||
Total equity | ( | ( | ||||||||
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account. | ||||||||||
Approved by the board on 09 July 2025 and signed on its behalf by: | ||||||||||
D. Mevzos | ||||||||||
Director | ||||||||||
09 July 2025 | ||||||||||
Dasapharm Limited Notes to the Accounts Registrar |
for the year ended 31 December 2024 | ||||||||||||||
1 | General information | |||||||||||||
Dasapharm Limited is a private company limited by shares and incorporated in England and Wales. | ||||||||||||||
The company's registered number is: 09325869 | ||||||||||||||
The address of the company's registered office is: | ||||||||||||||
Going concern | ||||||||||||||
2 | Accounting policies | |||||||||||||
Turnover | ||||||||||||||
Revenue from the sale of goods is recognised when all the following conditions are satisfied: • the Company has transferred to the buyer the significant risks and rewards of ownership of the goods; • the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; • the amount of revenue can be measured reliably; • it is probable that the economic benefits associated with the transaction will flow to the Company; and • the costs incurred or to be incurred in respect of the transaction can be measured reliably. Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed. | ||||||||||||||
Intangible fixed assets | ||||||||||||||
Tangible fixed assets and depreciation | ||||||||||||||
At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss. | ||||||||||||||
Furniture, fittings and equipment | ||||||||||||||
Research and development costs | ||||||||||||||
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years. | ||||||||||||||
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only. | ||||||||||||||
Taxation | ||||||||||||||
Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. | ||||||||||||||
Stocks | ||||||||||||||
Stocks are stated at the lower of cost and net realisable value. Net realisable value is based upon estimated selling prices less further costs expected to be incurred to disposal. | ||||||||||||||
At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the statement of comprehensive income. | ||||||||||||||
Trade and other debtors | ||||||||||||||
Trade and other creditors | ||||||||||||||
Foreign currencies | ||||||||||||||
Judgements and key sources of estimation uncertainty | ||||||||||||||
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors including expectations of future events that are believed to be reasonable under the circumstances. | ||||||||||||||
Financial instruments | ||||||||||||||
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable. | ||||||||||||||
Cash and cash equivalents | ||||||||||||||
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. | ||||||||||||||
Loans and borrowings | ||||||||||||||
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. | ||||||||||||||
3 | Employees | |||||||||||||
2024 | 2023 | |||||||||||||
Number | Number | |||||||||||||
The average monthly number of employees (including directors) during the year was: | ||||||||||||||
4 | Intangible fixed assets | |||||||||||||
Development costs | Total | |||||||||||||
$ | $ | |||||||||||||
Cost | ||||||||||||||
Additions | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Amortisation and impairment | ||||||||||||||
Charge for the year | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Net book values | ||||||||||||||
At 31 December 2024 | ||||||||||||||
5 | Tangible fixed assets | |||||||||||||
Fixtures, fittings and equipment | Total | |||||||||||||
$ | $ | |||||||||||||
Cost or revaluation | ||||||||||||||
At 1 January 2024 | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Depreciation | ||||||||||||||
At 1 January 2024 | ||||||||||||||
Charge for the year | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Net book values | ||||||||||||||
At 31 December 2024 | ||||||||||||||
At 31 December 2023 | 2,032 | |||||||||||||
6 | Stocks | |||||||||||||
2024 | 2023 | |||||||||||||
$ | $ | |||||||||||||
Finished goods | ||||||||||||||
7 | Debtors | |||||||||||||
2024 | 2023 | |||||||||||||
$ | $ | |||||||||||||
Trade debtors | ||||||||||||||
VAT recoverable | ||||||||||||||
Other debtors | ||||||||||||||
Prepayments and accrued income | ||||||||||||||
8 | Creditors: | |||||||||||||
amounts falling due within one year | ||||||||||||||
2024 | 2023 | |||||||||||||
$ | $ | |||||||||||||
Trade creditors | ||||||||||||||
Amounts owed to group undertakings | ||||||||||||||
Accruals and deferred income | ||||||||||||||
9 | Share Capital | |||||||||||||
The company has 100 ordinary share of $1.34 each, amounting to a share capital of $134 (2023: $134). | ||||||||||||||
10 | Reserves | |||||||||||||
11 | Related party disclosures | |||||||||||||
Transactions with related parties | ||||||||||||||
There was a balance of $1,876,392 (2023: $1,388,126) made up of loans and management fees owed to Dasapharm Ltd (BVI) a company with a common Director. | ||||||||||||||